High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).
暂无分享,去创建一个
R. Emerson | G. Giaccone | E. Rock | Y. Bang | P. Moore | C. Sanders | H. Burris | S. Im | J. Trepel | J. Nordstrom | E. Yusko | Min-Jung Lee | K. Knutson | Sunmin Lee | C. Erskine | T. Bauer | E. Bonvini | J. Muth | J. Baughman